Form 4: Revolution Medicines Executive Sells Shares
Insider Transaction (Form 4)
Jeff Cislini, General Counsel of Revolution Medicines, Inc., sold 56,894 shares of common stock on August 21, 2026.
Summary
- Option exercise/conversion: acquired 29,680 Common Stock at $18.56 ($550,861) on August 21, 2026; holds 86,201 after (Direct).
- Option exercise/conversion: acquired 26,600 Common Stock at $21.61 ($574,826) on August 21, 2026; holds 112,801 after (Direct).
- Open-market sale: disposed of 3,400 Common Stock at $207.24 ($704,603) on August 21, 2026; holds 109,401 after (Direct).
- Open-market sale: disposed of 17,323 Common Stock at $208.37 ($3,609,573) on August 21, 2026; holds 92,078 after (Direct).
- Open-market sale: disposed of 25,817 Common Stock at $209.25 ($5,402,200) on August 21, 2026; holds 66,261 after (Direct).
- Open-market sale: disposed of 2,540 Common Stock at $210.26 ($534,072) on August 21, 2026; holds 63,721 after (Direct).
- Open-market sale: disposed of 4,500 Common Stock at $211.34 ($951,038) on August 21, 2026; holds 59,221 after (Direct).
- Open-market sale: disposed of 3,314 Common Stock at $212.06 ($702,761) on August 21, 2026; holds 55,907 after (Direct).
- Option exercise/conversion: disposed of 29,680 Stock Option (Right to Buy) on August 21, 2026 (Direct).
- Option exercise/conversion: disposed of 26,600 Stock Option (Right to Buy) on August 21, 2026; holds 3,500 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $11,904,247 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Jeff Cislini — Officer (General Counsel)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-21 | Option exercise/conversion | Common Stock | 29,680 | $19 | $550.9K | 86,201 |
| 2026-08-21 | Option exercise/conversion | Common Stock | 26,600 | $22 | $574.8K | 112,801 |
| 2026-08-21 | Open-market sale | Common Stock | 3,400 | $207 | $704.6K | 109,401 |
| 2026-08-21 | Open-market sale | Common Stock | 17,323 | $208 | $3.6M | 92,078 |
| 2026-08-21 | Open-market sale | Common Stock | 25,817 | $209 | $5.4M | 66,261 |
| 2026-08-21 | Open-market sale | Common Stock | 2,540 | $210 | $534.1K | 63,721 |
| 2026-08-21 | Open-market sale | Common Stock | 4,500 | $211 | $951.0K | 59,221 |
| 2026-08-21 | Open-market sale | Common Stock | 3,314 | $212 | $702.8K | 55,907 |
| 2026-08-21 | Option exercise/conversion | Stock Option (Right to Buy) | 29,680 | — | — | 0 |
| 2026-08-21 | Option exercise/conversion | Stock Option (Right to Buy) | 26,600 | — | — | 3,500 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-21 | Option exercise/conversion (29,680 shares) |
| 2026-08-21 | Option exercise/conversion (26,600 shares) |
| 2026-08-21 | Open-market sale (3,400 shares) |
| 2026-08-21 | Open-market sale (17,323 shares) |
| 2026-08-21 | Open-market sale (25,817 shares) |
| 2026-08-21 | Open-market sale (2,540 shares) |
| 2026-08-21 | Open-market sale (4,500 shares) |
| 2026-08-21 | Open-market sale (3,314 shares) |
| 2026-08-21 | Option exercise/conversion (29,680 shares) |
| 2026-08-21 | Option exercise/conversion (26,600 shares) |
Keywords
insider transaction, Form 4, RVMD, Revolution Medicines, Inc., bearish, Jeff Cislini
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.